O. L. Floch

Histologic multifocality is predictive of skin recurrences after conserving treatment of stage I and II breast cancers

B. Giraudeau, H. Marret, G. Body, 2001, Breast Cancer Research and Treatment.

The French 70 Gy versus 80 Gy dose escalation trial for localized prostate cancer: feasibility and toxicity

P. Maingon, N. Salem, J. Bachaud, 2003 .

A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix.

J. Horiot, D. Machin, S. Dische, 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients

S. Bourdin, P. Bey, M. Resbeut, 1996, Supportive Care in Cancer.

Prognostic significance of tumor phosphatidylcholine stearic acid level in breast carcinoma

C. Couet, V. Chajès, G. Body, 1991, Breast Cancer Research and Treatment.

Docosahexaenoic acid (DHA) intake during first line chemotherapy improves survival in metastatic breast cancer.

Marie-Ange Baucher, G. Body, P. Bougnoux, 2006 .

Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma

G. Calais, E. Germain, V. Chajès, 1999, British Journal of Cancer.

Cytotoxic drug efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma

G. Calais, E. Germain, V. Chajès, 2007, Lipids.

Low body mass index is an independent predictive factor of local recurrence after conservative treatment for breast cancer

H. Marret, G. Body, F. Perrotin, 2001, Breast Cancer Research and Treatment.

Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm

G. Calais, G. Body, J. Lansac, 1994, Cancer.